Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Tuesday broker round-up UPDATE

Tue, 28th Oct 2014 09:18

Afren: Credit Suisse lowers target price from 132p to 115p staying with its outperform rating.African Barrick Gold: Westhouse moves target price from 230p to 240p and keeps an add rating.Anglo American: Investec reduces target price from 1603p to 1588p and keeps a buy recommendation.APR Energy: Liberum Capital upgrades to hold with a target price of 385p. Jefferies reduces target price from 1250p to 670p, while its buy recommendation remains unchanged. JP Morgan reduces target price from 1008p to 801p and leaves its overweight rating unchanged.Aviva: Societe Generale raises target price from 580p to 650p maintaining a buy recommendation.Cairn Energy: Credit Suisse cuts target price from 288p to 266p and retains an outperform rating.Croda International: Goldman Sachs reduces target price from 2750p to 2675p, while leaving its buy recommendation unaltered.Direct Line: UBS cuts target price from 304p to 282p and stays with its buy recommendation.Dunelm: Canaccord initiates with a target price of 925p and a buy recommendation.easyJet: Deutsche Bank reduces target price from 1935p to 1830p keeping a buy recommendation.Elementis: Goldman Sachs cuts target price from 345p to 330p and stays with its neutral rating.EnQuest: Credit Suisse cuts target price from 150p to 122p reiterating an outperform rating.Essentra: Goldman Sachs reduces target price from 970p to 880p and retains a buy recommendation.Faroe Petroleum: Credit Suisse lowers target price from 138p to 133p and reiterates a neutral rating.GKN: Westhouse cuts target price from 450p to 400p and leaves its buy recommendation unchanged.GlaxoSmithKline: Jefferies cuts target price from 1400p to 1350p and reiterates a hold recommendation.HSBC Holdings: Deutsche Bank lowers target price from 640p to 638p and retains its hold recommendation.ICAP: Morgan Stanley ups target price from 386p to 408p staying with its equal-weight rating.LSE: Morgan Stanley raises target price from 2098p to 2210p and keeps an overweight rating.Mothercare: JP Morgan cuts target price from 267p to 238p maintaining an overweight rating.Old Mutual: Barclays downgrades to equal-weight with a target price of 205p. JP Morgan shifts target price from 223p to 225p and reiterates an overweight rating.Petra Diamonds: Panmure Gordon cuts target price from 171p to 155p leaving its sell recommendation unchanged.Premier Foods: Societe Generale cuts target price from 70p to 35p and retains its hold recommendation.Premier Oil: Credit Suisse reduces target price from 392p to 355p and reiterates an outperform rating.Shire: Cenkos increases target price from 5200p to 5347p keeping its buy recommendation.SIG: Numis cuts target price from 230p to 200p maintaining its buy recommendation.Standard Chartered: Numis reduces target price from 1400p to 1200p downgrading from add to hold. Investec reduces target price from 1450p to 1350p and stays with its buy recommendation.Stratex: Northland lowers target price from 9.3p to 7.7p and stays with its buy recommendation.Synthomer: Goldman Sachs lowers target price from 260p to 250p and reiterates its neutral rating. Canaccord cuts target price from 283p to 258p and retains a buy recommendation.Tullett Prebon: Morgan Stanley ups target price from 254p to 270p and retains its equal-weight rating.Tullow Oil: Credit Suisse lowers target price from 800p to 790p and keeps a neutral rating.UBM: Canaccord ups target price from 600p to 620p upgrading from hold to buy.Vedanta Resources: Deutsche Bank reduces target price from 1215p to 1180p maintaining a buy recommendation.Victrex: Goldman Sachs reduces target price from 2110p to 2010p and keeps a buy recommendation.Wetherspoon (JD): Numis ups target price from 900p to 950p leaving its add rating unchanged.
More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.